Lung Cancer

AstraZeneca’s Lung Cancer Duo Flops | Investopedia

In a fresh blow to the ambitious efforts of combining two immunotherapy drugs to fend off lung cancer, AstraZeneca’s (AZN) drug combination failed to …


AstraZeneca third-line lung cancer combination study fails | Reuters

LONDON (Reuters) - A combination of AstraZeneca immunotherapy drugs in lung cancer patients who have already received at least two previous treatments has failed to show a benefit in slowing disease progression or helping patients live longer.<p>A sign is seen at an AstraZeneca site in Macclesfield, …


EMA accepts Merck's marketing application for Keytruda for first-line lung cancer

The European Medicines Agency (EMA) accepts for review Merck's (NYSE:MRK) marketing application seeking approval for KEYTRUDA (pembrolizumab), in …


Merck Emerges As Dominant Player In Lung Cancer: Goonewardene

Bloomberg Markets AM with Pimm Fox and Lisa Abramowicz.<p>Guest: Asthika Goonewardene, Senior Biotech Analyst for Bloomberg Intelligence, on highlights …


Size, structure help poziotinib pose threat to deadly exon 20 lung cancer: MD Anderson Lung Cancer Moon Shot™ research matches drug to defiant mutation

MD Anderson Lung Cancer Moon Shot™ research matches drug to defiant mutation<p>A drug that failed to effectively strike larger targets in lung cancer …


Goldman upgrades Merck, calls it one of the firm's favorite stocks because of Keytruda lung cancer breakthrough

Goldman Sachs upgraded shares of Merck to buy from neutral and named it to its Americas Conviction List of favorite stocks on Monday because of …


170 potential lung cancer drug targets identified

Scientists, who tested over 200,000 chemical compounds, have identified 170 candidates that can be potentially used for developing new drug therapies …


アストラゼネカのタグリッソ、EGFR変異陽性非小細胞肺がんの1次治療として、米国食品医薬品局 (FDA)より承認取得 - CNET Japan

~タグリッソによる1次治療が新たな標準治療を提供する可能性~ ~既存の標準治療の10.2カ月に対し、かつてない18.9カ月の無増悪生存期間を達成~<p>本資料はアストラゼネカ英国本社が2018年4月18日に発信したプレスリリースを日本語に翻訳し、みなさまのご参考に提供するものです。本資料の正式言語は英語であり、その内容・解釈については英語が優先します。<p>アストラゼネカ(本社:英国ケンブリッジ、最高経営責任者(CEO):パスカル・ソリオ[Pascal Soriot]、以下、アストラゼネカ)は、2018年4月18日、タグリッソ …


Immune therapy plus chemo doubles lung cancer survival, study says

Chemotherapy and radiation are common treatments for lung cancer. However, immune therapy may be able to help double a patient’s survival, according …


LISTEN: The Coke and Pepsi of lung cancer, a debatable drug price, and a cure for capitalism

Is Bristol-Myers Squibb into self-sabotage? Is Congress coming for Gut Guy? And why does Goldman Sachs love money so much?We delve into all that and …


AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug

(Reuters) - U.S. regulators have expanded use of AstraZeneca's lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday.<p>The latest Food and Drug Administration approval includes patients with metastatic non-small cell lung …


Crizotinib active in patients of East Asian ethnicity

In Brief<p>LUNG CANCER<p>Cancer genetics<br>• Non-small-cell lung cancer<br>• Targeted therapies<p>Subscribe to <i>Nature Reviews Clinical Oncology</i> for full …


Drugs that boost immune system activity could be key in treating lung cancer

Expensive, $13,000 per-month immunotherapy treatment is being considered as a frontline treatment in the fight against lung cancer after tests show promising results.


Slideshow: Surprising Signs You Might Have Lung Cancer


Possible breakthrough on lung cancer

Research into the treatment of lung cancer has achieved a possible breakthrough - after a new study showed survival times were nearly doubled for some patients - by combining the use of immunotherapy drugs with chemotherapy.<p>Oncologists have described the findings as "huge".<p>"We're going to have to …


Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients

Article<p>Cristina Pérez-Ramírez,<br>• Marisa Cañadas-Garre ORCID:,<br>• Ahmed Alnatsha,<br>• Eduardo Villar,<br>• Javier Valdivia-Bautista,<br>• María …

Google Scholar

Can a simple blood test rule out lung cancer?

A blood test to measure the levels of two proteins in plasma that are common predictors of lung cancer was 98 percent effective in a multicenter …


Immunotherapy transforms lung cancer, the biggest cancer killer

Combinations, pre-surgery treatment both help stop cancer spread<p>Immune therapy drugs can transform lung cancer treatment, giving patients years of extra life, doctors reported Monday.<p>They found that pre-treating lung cancer patients with immune therapy drugs before they have surgery can help melt …


'We are going to have lung cancer patients living longer and better:' A new kind of cancer treatment is about to change how we treat the disease

A new kind of cancer treatment that harnesses the body's immune system, known as immunotherapy, is going mainstream.<p>In data presented Monday at the American Association of Cancer Research's annual meeting, Merck showed that a combination of the immunotherapy Keytruda with chemotherapy was able to …


Immune therapy scores big win against lung cancer in study

New research suggests that many more lung cancer patients may benefit from treatments that boost the immune system, which have scored some of their biggest wins until now in less common forms of the disease.<p>One study found using one of these drugs — Merck's Keytruda (kee-TROO-dah) — with usual …


New Drug Combinations Improve Survival in Lung Cancer

Immunotherapies boost patient survival rates, studies show, but come with high price tags<p>Combining new immune-boosting cancer drugs with each other or with older drugs improved survival in patients with lung cancer, compared with traditional chemotherapy, new studies found.<p>The benefits of the new …


Immunotherapy study yields unexpectedly strong results for lung cancer patients

Researchers in Chicago presented new data Monday that has big implications for lung cancer patients. A clinical trial discovered that pairing …


Merck Jumps, Bristol-Myers Slumps on Lung Cancer Study Data

Shares of Merck & Co. (MRK) climbed on Monday, April 16, while Bristol-Myers Squibb Co. (BMY) shares dropped after the drugmakers released data from …


Merck Cements Lead in Lung Cancer With Bristol-Myers Fizzling

Merck & Co. might have just shut the door on rival Bristol-Myers Squibb Co. as investors weigh new data that could reshape the treatment of lung …


Merck shares surge anew on lung cancer advance, while Bristol-Myers stock plummets

The pairing of Keytruda and chemotherapy reduced risk of death for patients with advanced lung cancer by half, a significant improvement.


Merck Expands Lead in Lung Cancer Therapy

Merck & Co. is cementing its lead in lung cancer therapy, fending off rival Bristol-Myers Squibb Co. after new data that could reshape treatment of …


Utah ranks among U.S. states with highest rates of lung cancer caused by air pollution, report says

When Thomas Varghese relocated from Seattle to take a job at the University of Utah, his colleagues warned him he wouldn’t make much use of his …


[$$] Bristol-Myers Has Farther to Fall

Bristol-Myers Squibb shareholders have a valuation problem after releasing mixed clinical data in a carefully watched trial for patients with lung …


2 cancer drugmakers just presented key data about how new treatments work in lung cancer — and the markets picked a winner (MRK, BMY)

• <b>Two cancer drugmaker rivals presented data on Monday about how combinations of their drugs, which harness the body's immune system to treat cancer, worked in treating a common form of lung cancer compared to traditional chemotherapy.</b>• <b><br>Merck showed that its drug Keytruda in combination with</b> …


Brainstorm Health: Merck's Lung Cancer Triumph, COPD and Women, Trump on Drug Prices

Hello and happy Monday, readers! This is Sy.<p>New study results released Monday continue to cement drug giant Merck’s status as the force to be …